To the best of our knowledge, this study is the first report demonstrating the possibility that SGLT2 inhibitors can induce autophagy in non-diabetic or metabolically normal mouse kidneys whereas previous studies on SGLT2 inhibitors and autophagy mainly focused on the mouse models of diabetes or obesity [34, 47]. Here, SLC5A2 is linked to diabetes mellitus.